Type | Public |
---|---|
Industry | Product and technology development and consultancy |
Founded | 1986 |
Headquarters | Cambridge, England Cambridge, Massachusetts |
Employees | 150 |
Website | www.sagentia.com |
Contents |
Sagentia, formed as Scientific Generics in 1986, is an international product development and technology consulting organisation. In 2006, the company changed its name to Sagentia [1] to coincide with the company’s 20th anniversary.
Sagentia’s heritage is linked to that of the 'Cambridge Phenomenon' – the high technology cluster based around Cambridge University in the UK that emerged in the 1980s. Sagentia was founded by Professor Gordon Edge, one of a small number of key individuals who have played a central role in the development of the cluster into the globally recognised position that it occupies today. The company grew through the 80s and 90s, moving headquarters from their initial base near the Cambridge Science Park to the current location in Harston, just south of the city of Cambridge in 1995.
Sagentia Group is currently listed on the Alternative Investment Market (AIM), and is a founder member of the Cambridge Network.
The CEO is Brent Hudson, appointed in 2009 [2]. In 2010, Martyn Ratcliffe purchased a significant stake in the company and was appointed Chairman [3].
Sagentia currently operates in 3 key global market sectors: medical, consumer products and industrial products.
The range of services offered cuts across all market sectors including product development, design and build, intellectual property analysis and strategy and opportunity discovery at the front end of innovation.
Clients include: Johnson & Johnson; AstraZeneca; BT; Department of Trade & Industry; Hasbro; PepsiCo; Vodafone.
The company has offices around the world: Cambridge, England; Cambridge, Massachusetts, USA; Hong Kong and is ISO certified: ISO 9001:2008 and ISO 13485:2003.
The company has won several awards in recent years:
Sagentia created many spin-out companies over the years, including:
In 2008 the company announced a change in direction moving away from venturing and focusing on the core consulting business.